1. Franciosini MP, Davidson I. A walk through Gumboro disease. Poultry. 2022;1(4):229-42.
2.Eterradossi N, Saif YM. Infectious bursal disease. Diseases of poultry. 2013:219-46.
3.Jackwood DJ, Sommer-Wagner S. Genetic characteristics of infectious bursal disease viruses from four continents. Virology. 2007;365(2):369-75.
4.Van den Berg H, Faulks R, Granado HF, Hirschberg J, Olmedilla B, Sandmann G, et al. The potential for the improvement of carotenoid levels in foods and the likely systemic effects. Journal of the Science of Food and Agriculture. 2000;80(7):880-912.
5.Boudaoud A, Mamache B, Tombari W, Ghram A. Virus mutations and their impact on vaccination against infectious bursal disease. Rev Sci Tech. 2016;35(3):875-97.
6.Najafi H, Hosseini H, Kasaee M, Aghaiyan L, ZiafatiKafi Z, Hajizamani N, et al. Molecular characterization of a very virulent Infectious Bursal Disease Virus from Iran demonstrates its similarity with recent isolates from the Middle East. Iranian Journal of Virology. 2018;12(2):1-5.
7.Norouzian H, Farjanikish G, Hosseini H. Genetic and pathologic characteristics of infectious bursal disease viruses isolated from broiler chickens in Iran during 2014–2015. Acta Virol. 2017;61(2):191-6 [In Persian].
8.Alam J, Rahman M, Sil B, Khan M, Sarker M. Effect of maternally derived antibody on vaccination against infectious bursal disease with live vaccine in broiler. International Journal of Poultry Science. 2002;1(4):98-101.
9.De Wit J. Gumboro disease: estimation of optimal time of vaccination by the Deventer formula. Annual report and proceedings of COST Action. 2001;839:170-8.
10.Isihak FA, Ismail HK, Wahid AA. Comparison study between the efficacy of immune complex and conventionally live vaccine against Gumboro disease in broilers. 2021[In Persian].
11.Ebrahimi M, Yousefi A, Zaghari M, Bassami M. Comparison of the immunogenicity of four infectious bursal disease intermediate vaccines in commercial broiler flocks in Iran: A Field Trial Study. Archives of Razi Institute. 2020;75(2):205[In Persian].
12.Lasher H, Shane S. Infectious bursal disease. World's Poultry Science Journal. 1994;50(2):133-66.
13.Nagy A, Mettenleiter TC, Abdelwhab E. A brief summary of the epidemiology and genetic relatedness of avian influenza H9N2 virus in birds and mammals in the Middle East and North Africa. Epidemiology & Infection. 2017;145(16):3320-33.
14.Elfeil W, Abouelmaatti R, Diab M, Mandour M, Rady M. Experimental infection of chickens by avian influenza H9N2 virus: monitoring of tissue tropism and pathogenicity. J Egypt Vet Med Assoc. 2018;78(3):369-83.
15.Sultan HA, Talaat S, Elfeil WK, Selim K, Kutkat MA, Amer SA, et al. Protective efficacy of the Newcastle disease virus genotype VII-matched vaccine in commercial layers. Poult Sci. 2020;99(3):1275-86.
16.Kilany WH, Ali A, Bazid AH, El-Deeb AH, El-Abideen MA, Sayed ME, et al. A Dose-Response Study of Inactivated Low Pathogenic Avian Influenza H9N2 Virus in Specific-Pathogen-Free and Commercial Broiler Chickens. Avian Dis. 2016;60(1 Suppl):256-61.
17.Younis Z, Isihak F. Immunological assessment and homogeneity of commercial inactivated bivalent Newcastle and avian influenza H9N2 vaccines in broilers. Iraqi Journal of Veterinary Sciences. 2025;39(3):501-10.
18.Shaukat T, Muneer M, Ahmad M, Maqbool A, Shaukat T. Efficacy of avian influenza virus locally manufactured and imported vaccines. 2016.
19.Sun Y, Pu J, Fan L, Sun H, Wang J, Zhang Y, et al. Evaluation of the protective efficacy of a commercial vaccine against different antigenic groups of H9N2 influenza viruses in chickens. Veterinary microbiology. 2012;156(1-2):193-9.
20.Pan X, Su X, Ding P, Zhao J, Cui H, Yan D, et al. Maternal-derived antibodies hinder the antibody response to H9N2 AIV inactivated vaccine in the field. Animal Diseases. 2022;2(1):9.